First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase 3 iLLUMINATE trial.

Moreno, C; Greil, R; Demirkan, F; Tedeschi, A; Anz, B; Larratt, L; Simkovic, M; Novak, J; Strugov, V; Gill, D; Gribben, JG; Kwei, K; Dai, S; Hsu, E; Dean, JP; Flinn, IW; Haematologica. 2022;

Transcriptomic Profiling Identifies CD8(+ )T Cells in the Brain of Aged and Alzheimer?s Disease Transgenic Mice as Tissue-Resident Memory T Cells

Altendorfer, B; Unger, MS; Poupardin, R; Hoog, A; Asslaber, D; Gratz, IK; Mrowetz, H; Benedetti, A; de Sousa, DMB; Greil, R; Egle, A; Gate, D; Wyss-Coray, T; Aigner, L J IMMUNOL. 2022; 209(7): 1272-1285.

Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial

Tam, CS; Brown, JR; Kahl, BS; Ghia, P; Giannopoulos, K; Jurczak, W; Simkovic, M; Shadman, M; Osterborg, A; Laurenti, L; Walker, P; Opat, S; Chan, HR; Ciepluch, H; Greil, R; Tani, M; Trneny, M; Brander, DM; Flinn, IW; Grosicki, S; Verner, E; Tedeschi, A; Li, JY; Tian, T; Zhou, L; Marimpietri, C; Paik, JC; Cohen, A; Huang, JN; Robak, T; Hillmen, P LANCET ONCOL. 2022; 23(8): 1031-1043.

How I treat diffuse large B-cell lymphoma.

Melchardt, T; Egle, A; Greil, R; ESMO Open. 2023; 8(1):100750

Barriers to patient access of CAR T cell therapies in Austria

Hopfinger, G; Rupp, B; Greil, R MEMO-MAG EUR MED ONC. 2023;

Targets of autoantibodies in acquired hemophilia A are not restricted to factor VIII: data from the GTH-AH 01/2010 study.

Oleshko, O; Werwitzke, S; Klingberg, A; Witte, T; Eichler, H; Klamroth, R; Holstein, K; Hart, C; Pfrepper, C; Knoebl, P; Greil, R; Neumeister, P; Reipert, BM; Tiede, A Blood Adv. 2023; 7(1):122-130

Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer.

Wagner, SM; Magnes, T; Melchardt, T; Kiem, D; Weiss, L; Neureiter, D; Wagner, C; Aretin, MB; Nemec, S; Gamerith, G; Pall, G; Greil, R; Fuereder, T; Anticancer Res. 2023; 43(3):1273-1282

Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12.

Beltran-Bless, AA; Clemons, MJ; Fesl, C; Greil, R; Pond, GR; Balic, M; Vandermeer, L; Bjelic-Radisic, V; Singer, CF; Steger, GG; Helfgott, R; Egle, D; Sölkner, L; Gampenrieder, SP; Kacerovsky-Strobl, S; Suppan, C; Ritter, M; Rinnerthaler, G; Pfeiler, G; Fohler, H; Hlauschek, D; Hilton, J; Gnant, M; Eur J Cancer. 2023; 180:108-116